Tag: patients
How AI and Data Analytics Will Impact The Era of COVID-19
Artificial intelligence (AI) and data analytics are rapidly growing trends in the tech world. With increasing potential for innovation, it is paramount that we stay up to date with all the latest developments in this field. According to MarketsandMarkets, the worldwide artificial intelligence (AI) market will increase from USD 58.3 billion IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA
 |
SM17 is the world's first monoclonal antibodies targeting IL17BR co-developed by SinoMab and LifeArc (a medical research charity based in the United Kingdom). SM17 has a wide range of indications, including indications with large market volumes such as asthma and diseases with high mortality rates such as idiopathic pulmonary fibrosis. Comparing to other products on the market, SM17 enjoys differentiation advantages. With the preclinical data and unique mechanism of action of SM17, Company believes that SM17 potentially has a broader and more beneficial effect on asthma treatment than other approved biologics.
In the global market, the number of asthma patients is gradually increasing and is expected to reach 247.5 million by 2023 and further increase to 267.7 million by 2030. The number of asthma patients in the PRC is increasing at a greater pace than the global rate and is forecasted to reach 25.6 million by 2023 and further increase to 27.8 million by 2030. In terms of market size, the global asthma market is projected to reach US$25.1 billion by 2023 and US$34.6 billion by 2030. However, the asthma market in the PRC is expected to reach RMB36.4 billion by 2023 and RMB65.0 billion by 2030. In terms of treatment options, traditional asthma treatment is based on inhaled corticosteroid, but they are prone to serious adverse effects, especially in adolescents. Drug resistance can also develop if used for a long time. The introduction of SM17 is expected to provide a better treatment option in terms of the balance of efficacy and safety.
Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "following the acceptance of the IND application for SN1011 for the treatment of multiple sclerosis by the NMPA, the acceptance of the SM17 IND application by the FDA fully demonstrates the efficient execution of the Company's new drug R&D program. There is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. We are therefore confident in the enormous prospects of SM17's clinical development. Our core products, including SM03, SN1011 and SM17, is making progress on the clinical R&D smoothly, driving the Company moving steadily towards commercialization. In the future, we will accelerate our projects implementation to bring benefits to patients and create value for shareholders through innovation."
About SM17
SM17 is known to be the world's first humanized, IgG4-k monoclonal antibody for new drug development, which targets IL-17RB. And IL-17RB is a type-I single transmembrane glycoprotein belonging to IL-17 receptor family. The binding of SM17 to IL-17RB could suppress Th2 immune responses induced by a category of cytokines called "alarmin", which has shown to be implicated in the pathogenesis of allergic disease and airway viral responses. Alternative approach targeting upstream mediators of the Th2 inflammatory cascade, such as "alarmins", is expected to have a broader effect on airway inflammation and to provide more effective asthma control than currently available therapies, and products with similar mechanism of action as SM17 have been approved by FDA.
About SinoMab BioScience Limited
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases
Cannabis Legends to Remember During Black History Month
Unfortunately, the War on Drugs has made it difficult for African Americans to succeed in the cannabis industry. It’s also harder on Black Americans, who are 4 times more likely to be arrested for marijuana-related charges compared to white people. For them, getting a slice of the cannabis pie is much more challenging. Because of that, and because it’s Black History Month, here are some of the most notable African American pioneers in cannabis that deserve recognition for their achievements in the challenging industry. Let’s allow them to inspire the next generation of African-American cannabis trailblazers:
VCBC fined $6.5 million – Canada’s oldest compassion club faces heavy enforcement from the province
Canada’s oldest compassion club, The Victoria Cannabis Buyers Club is fighting to survive, thanks to aggressive provincial enforcement. The non-profit club was raided in November 2109 and again in July of 2020. At the end of January, the VCBC received a letter from the CSU and a whopping $6.5 million dollar fine. Earlier this week, […]
The post VCBC fined $6.5 million – Canada’s oldest compassion club faces heavy enforcement from the province appeared first on Latest Cannabis News Today - Headlines, Videos & Stocks.
Did OGI cause brain disorders in NB? Study, yeast causes Alzheimer’s
Cannabis consumption has yet to cause a single death. A licensed cannabis producer in Canada, Organigram (OGI), did indirectly lead to the unfortunate death of Jumpin’ Jack Proud, though. Back in August of 2019, CBC reported internal emails from the cannabis producer regarding cooling towers clogged with bacteria. In December of 2020, Organigram admitted that […]
The post Did OGI cause brain disorders in NB? Study, yeast causes Alzheimer’s appeared first on Latest Cannabis News Today - Headlines, Videos & Stocks.
Latest Intelligence
